International Journal of Clinical Pharmacy最新文献

{"title":"Effectiveness of continuous pharmacist intervention at maintaining dose intensity in postoperative adjuvant S-1 chemotherapy for gastric cancer: a multicentre retrospective study.","authors":"Toshinobu Hayashi, Makiko Go, Kenji Kawasumi, Kazuyoshi Kawakami, Reiko Matsui, Hironori Fujii, Takanori Miyoshi, Tomoaki Eto, Makoto Kajizono, Tatsuya Ohtsubo, Yumi Morioka, Kyohei Yamaguchi, Akihiro Ogawa, Toshihisa Nakashima, Maki Todo, Koichi Matsuo","doi":"10.1007/s11096-026-02200-5","DOIUrl":"10.1007/s11096-026-02200-5","url":null,"abstract":"<p><strong>Introduction: </strong>Maintaining dose intensity is essential for ensuring the efficacy of adjuvant S-1 chemotherapy in gastric cancer. Although pharmacist interventions can reduce toxicity and improve adherence, multicentre evidence regarding their impact on dose maintenance is limited.</p><p><strong>Aim: </strong>This study aimed to evaluate the effectiveness of continuous pharmacist intervention on the eight-cycle treatment completion rate and relative performance (RP) in patients with gastric cancer undergoing outpatient S-1 adjuvant chemotherapy.</p><p><strong>Method: </strong>This multicentre retrospective study analysed 225 patients across 12 institutions, categorised into the continuous intervention (n = 97) and non-continuous intervention (n = 128) groups. Continuous intervention was defined as systematic monitoring and management for at least 50% of the treatment duration. Inverse probability of treatment weighting was used to adjust for baseline covariates. The primary and secondary endpoints were the eight-cycle completion rate and RP value, respectively.</p><p><strong>Results: </strong>The eight-cycle completion rate did not differ significantly between the continuous and non-continuous intervention groups (53.0% vs. 55.2%, p = 0.775), nor did the frequency of treatment modification events, including discontinuation or dose reduction. However, the RP value was significantly higher in the continuous intervention group than in the non-continuous intervention group (73.7% vs. 64.9%, p = 0.038). This finding was robustly supported by sensitivity analysis between these two groups (75.1% vs. 61.1%, p = 0.0008). Overall, the continuous group maintained a high intervention rate (89.1%) throughout the final cycle, providing significantly more supportive care interventions than the non-continuous intervention group (53.2% vs. 4.9%, p < 0.001).</p><p><strong>Conclusion: </strong>Although continuous pharmacist intervention did not improve the treatment completion rate, it was essential for maintaining RP values above the clinically essential 70% threshold through proactive toxicity management and dynamic dose optimisation. These findings suggest that systematic pharmaceutical care contributes significantly to ensuring the quality and intensity of adjuvant chemotherapy.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"2149-2157"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148619860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deprescribing opportunities for patients with advanced non-small cell lung cancer: an observational study of potentially inappropriate medications and stakeholders' perspectives.","authors":"Fenna de Vries, Eva Verbeek, Arthur Smit, Michel van den Heuvel, Rob Ter Heine, Eric Franssen","doi":"10.1007/s11096-026-02158-4","DOIUrl":"10.1007/s11096-026-02158-4","url":null,"abstract":"<p><strong>Introduction: </strong>Polypharmacy (concurrent use of ≥ 5 medications) is common in patients with non-small cell lung cancer and increases the risk of potentially inappropriate medication use, particularly in those with advanced disease. Deprescribing may reduce medication-related harm; however, its implementation in oncology remains limited and is insufficiently informed by stakeholder perspectives.</p><p><strong>Aim: </strong>This study aimed to determine the prevalence of potentially inappropriate medications in patients with advanced non-small cell lung cancer and explore the attitudes and beliefs of patients, caregivers, and healthcare professionals regarding deprescribing to inform feasible implementation strategies for routine clinical practice.</p><p><strong>Method: </strong>A retrospective analysis was conducted in a cohort of 817 patients with stage IV non-small cell lung cancer to identify potentially inappropriate medications using the OncoSTRIP checklist. Perspectives on deprescribing were collected using validated questionnaires: the revised Patients' Attitudes Toward Deprescribing (rPATD) for patients and caregivers and the Comprehensive Healthcare Providers' Opinions, Preferences, and Attitudes Toward Deprescribing (CHOPPED) for medical clinicians and pharmacists, which were completed by 37 patients, 15 caregivers, 24 medical clinicians (physicians and specialist nurses), and 24 pharmacists.</p><p><strong>Results: </strong>Potentially inappropriate medications were algorithm-flagged in 793 of the 817 (97.1%) patients. Among these, 1,686 (40.8%) were confirmed by clinical evidence, while 2,448 (59.2%) were unconfirmed (defined as medications flagged by the checklist but lacking sufficient electronic health record data, such as laboratory values or specific indications, to definitively justify their use). The primary classifications were the risk of adverse drug events (47.3%) and unnecessary therapy (30.0%). Most patients (33, 89.2%) and caregivers (11, 73.3%) were willing to discontinue their medications if advised by a physician. Perceived barriers influenced medical clinicians' and pharmacists' willingness: medical clinicians were most affected by collaboration- and competence-related concerns, whereas pharmacists were constrained by competence- and patient-related factors.</p><p><strong>Conclusion: </strong>The high algorithm-flagged prevalence of potentially inappropriate medications with 40.8% confirmed by clinical evidence, in patients with advanced non-small cell lung cancer underscores the urgent need for deprescribing. Successful implementation requires a patient-centered approach, active involvement of patients and caregivers, interprofessional collaboration, and targeted strategies to address systemic and professional barriers to ensure safe and sustainable medication optimization.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1858-1870"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147929137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles and impacts of pharmacists in attention-deficit hyperactivity disorder services: a scoping review.","authors":"Muhammad Umair Khan, Atta Abbas Naqvi, Ian Chi-Kei Wong, Ian Maidment, Graham Brown, Samuele Cortese","doi":"10.1007/s11096-026-02184-2","DOIUrl":"10.1007/s11096-026-02184-2","url":null,"abstract":"<p><strong>Introduction: </strong>Demand for attention-deficit hyperactivity disorder (ADHD) services has increased substantially across health systems, placing pressure on specialist services and contributing to prolonged waiting times and inconsistent medication monitoring. Pharmacists have established expertise in medicines optimisation and, in some settings, are authorised to prescribe. Yet their role within ADHD care pathways remains poorly characterised.Kindly check and confirm the inserted city name in affiliations 3, 5, 6 and country name in affiliation 6 are correct and amend if necessary.Changes have been made, where necessary.   AIM: This scoping review aims to map the existing empirical evidence on pharmacist involvement in ADHD services, synthesise reported roles and impacts, and identify key evidence gaps to inform future research and service development.</p><p><strong>Method: </strong>A scoping review was conducted in accordance with the Arksey and O'Malley framework and reported using PRISMA-ScR guidance. Six databases (PubMed, PsycINFO, Embase, CINAHL, Scopus, and Web of Science) were searched from inception to December 2025. Empirical studies evaluating implemented pharmacist involvement in ADHD services were included, irrespective of study design. Data were charted and synthesised narratively across domains relating to clinical care, service delivery, economic outcomes, and barriers to implementation.</p><p><strong>Results: </strong>Thirteen studies were included, published between 2008 and 2025, primarily from the United States and the United Kingdom. Most were service evaluations or pre-post studies, with one randomised trial. Pharmacists were involved in a broad range of activities, including medication initiation, titration, monitoring, follow-up, patient education, and service governance, often as independent prescribers or within collaborative multidisciplinary models. Reported impacts included improved adherence to recommended monitoring standards, increased service capacity, reduced waiting times, and more efficient workforce utilisation, with some evidence of potential cost savings. However, outcome measures varied widely, and patient-reported outcomes, comparative effectiveness, and implementation processes were inconsistently examined.</p><p><strong>Conclusion: </strong>This review identifies a small but expanding evidence base indicating potential roles for pharmacists in ADHD services, particularly in medicines management and service delivery. However, the absence of clearly defined service models and limited comparative and implementation-focused evidence constrain wider adoption across health systems. Further research is needed to inform scalable and sustainable approaches to pharmacist integration in ADHD care.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1812-1826"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148445899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriateness of perioperative albumin administration in gastrointestinal tumor surgery patients without hypoalbuminemia: a propensity score-matched study.","authors":"Qian Ni, Fei Zhao, Lin Tan, Yi-Chun Wang, Peng-Fei Jin","doi":"10.1007/s11096-026-02185-1","DOIUrl":"10.1007/s11096-026-02185-1","url":null,"abstract":"<p><strong>Introduction: </strong>Human albumin is frequently administered during perioperative care because of its physiological role in maintaining plasma oncotic pressure and modulating the inflammatory response. However, increasing evidence suggests that albumin is often prescribed outside guideline-supported indications, particularly in surgical patients with preserved serum albumin levels. However, the clinical benefits of perioperative albumin administration in this population remain uncertain.</p><p><strong>Aim: </strong>To evaluate the association between perioperative albumin administration and short-term postoperative outcomes in patients undergoing gastrointestinal tumor surgery with preserved preoperative serum albumin concentrations.</p><p><strong>Method: </strong>This retrospective cohort study included adult patients who underwent gastrointestinal tumor resection at a tertiary teaching hospital. Patients with preoperative serum albumin concentrations ≥ 31 g/L were eligible. Propensity score matching (1:1) was used to balance the baseline characteristics between patients who received perioperative albumin and those who did not. The primary outcome was the incision drainage volume on postoperative day 2. Secondary outcomes included cumulative incision drainage volume on postoperative days 1-3, recovery-period serum albumin concentration, and postoperative hospital length of stay. Multivariable linear regression analyses were performed to evaluate the association between albumin administration and the outcomes.</p><p><strong>Results: </strong>After propensity score matching, 248 patients (124 per group) were included in the final analysis of the study. Perioperative albumin administration was not associated with reduced incision-drainage volume on postoperative day 2 or during postoperative days 1-3 (p > 0.05). Albumin administration was independently associated with higher recovery-period serum albumin concentrations (t = 3.996, p < 0.001). However, patients receiving albumin had significantly longer postoperative hospital stays than those who did not (p = 0.002).</p><p><strong>Conclusion: </strong>Among patients undergoing gastrointestinal tumor surgery with preserved preoperative serum albumin levels, perioperative albumin administration was not associated with improvements in early postoperative drainage outcomes and was associated with longer hospitalization, despite increasing serum albumin levels. These findings suggest that routine perioperative albumin administration in patients without hypoalbuminemia may provide limited clinical benefits and should be carefully evaluated in clinical practice.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"2038-2049"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacovigilance signal detection of rilonacept using FAERS with exploratory Mendelian randomization analysis.","authors":"Lihong Liu, Zhenfei Chi, Zhe Zhang","doi":"10.1007/s11096-026-02212-1","DOIUrl":"https://doi.org/10.1007/s11096-026-02212-1","url":null,"abstract":"<p><strong>Introduction: </strong>Rilonacept, an interleukin-1 (IL-1) \"trap,\" is FDA-approved for recurrent pericarditis, but research on its adverse reactions is limited due to its recent introduction.</p><p><strong>Aim: </strong>This study utilized FDA Adverse Event Reporting System (FAERS) to screen potential rilonacept-related adverse events, and further performed Mendelian randomization (MR) analysis to explore genetic associations related to IL-1 pathway modulation with these adverse events.</p><p><strong>Method: </strong>We analyzed all adverse event reports related to rilonacept from the FAERS database between January 2021 and June 2024. Positive signals for adverse reactions were extracted using reporting odds ratios (ROR) and proportional reporting ratio (PRR). MR analysis was conducted using genetic variants of IL1RN as instrumental variables to explore associations between IL1RN genetic variation and identified adverse reactions, with sensitivity analyses performed for robustness.</p><p><strong>Results: </strong>A total of 419 adverse event reports were analyzed, documenting 1847 adverse events (AEs). Common events include injection site erythema, injection site pain, and others, which are categorized into 27 System Organ Classes (SOCs). Notable frequencies were found in General disorders and administration site conditions, Skin and subcutaneous tissue disorders, and Injury, poisoning and procedural complications. Disproportionality analysis identified positive signals primarily in Cardiac Disorders, and Immune System Disorders, with 4 AEs showing positive signals in both Preferred Terms (PTs) and SOCs. MR analysis revealed significant associations between IL1RN genetic variation (used to explore rilonacept-related effects) and allergic urticaria (OR: 1.56 1.08-2.26) and myocarditis (OR: 2.26 1.63-3.14).</p><p><strong>Conclusion: </strong>Our study identified potential rilonacept AE signals via FAERS and IL1RN-genetic associations via MR (myocarditis was not detected in prior clinical trials). All findings serve solely to generate hypotheses for subsequent validation, and larger clinical datasets are needed to confirm these risks and optimize monitoring protocols.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of textual responses to explore barriers, enablers, and motivators for cultivating research capacity: a statewide study of hospital pharmacy staff.","authors":"Nadia Izzati Zamri, Nazanin Ghahreman-Falconer, Jacinta L Johnson, Sally B Marotti, Elizabeth McCourt, Sidony Miller-Waugh, Laetitia Hattingh","doi":"10.1007/s11096-026-02162-8","DOIUrl":"10.1007/s11096-026-02162-8","url":null,"abstract":"<p><strong>Introduction: </strong>Studies show that embedding research within healthcare services is associated with improved patient outcomes, enhanced workforce satisfaction, and increases in system performance. However, limited evidence exists regarding the research culture and capacity among hospital pharmacy staff in Australia.</p><p><strong>Aim: </strong>This research aimed to assess the research barriers, enablers, and motivators of a statewide public hospital pharmacy service at the organizational, team, and individual levels in Queensland, Australia.</p><p><strong>Method: </strong>This study forms part of a statewide, prospective, cross-sectional survey conducted across 16 public hospitals and health services in Queensland, Australia. Using the validated Research Capacity in Context Tool, data were collected via a survey that included open-ended questions to explore research barriers, enablers, and motivators. Reflexive, inductive thematic analysis was conducted to identify key themes and subthemes in free-text responses, with subthemes mapped against the Capability-Opportunity-Motivation-Behaviour model and the Theoretical Domains Framework.</p><p><strong>Results: </strong>Of the 481 survey participants, 401 provided open-ended responses. Six overarching themes and 14 subthemes were developed that influence research engagement. Themes are time and workload constraints, building research capacity, support from management, career progression and personal satisfaction, altruistic motivators, and navigating research processes. Lack of protected research time, limited access to resources, and variation in leadership support were prominent barriers to research uptake. Enablers of research uptake included availability of mentorship, interdisciplinary collaboration, intrinsic interest, and desire to contribute to patient-centered care.</p><p><strong>Conclusion: </strong>This study underscores the multifaceted barriers and enablers that act as motivators to cultivate research capacity within hospital pharmacy departments. Addressing concerns such as protected research time, mentorship, and streamlined governance processes is essential to nurturing a sustainable research culture.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1893-1903"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes of healthcare professionals towards the use of parenteral methotrexate in rheumatoid arthritis patients: a qualitative study.","authors":"Jiun Ming Tan, Wern Chern Chai, Nagham Ailabouni, Susanna M Proudman, Michael D Wiese, Emily Reeve","doi":"10.1007/s11096-026-02183-3","DOIUrl":"10.1007/s11096-026-02183-3","url":null,"abstract":"<p><strong>Introduction: </strong>Methotrexate is a cornerstone disease-modifying antirheumatic drug for rheumatoid arthritis (RA), effectively controlling disease activity and reducing cardiovascular mortality. Despite its efficacy, parenteral methotrexate, which offers higher bioavailability, faster response, and fewer gastrointestinal side effects compared to oral administration, remains underutilized in clinical practice. Understanding the factors influencing its utilization is critical to improving RA management.</p><p><strong>Aim: </strong>To explore the barriers and enablers towards using parenteral methotrexate in rheumatoid arthritis patients from the perspective of Australian healthcare professionals (HCPs).</p><p><strong>Method: </strong>A qualitative study was conducted using semi-structured interviews between May and August 2022. Participants were recruited via advertising and snowballing. The Theoretical Domains Framework was used to guide the development of the interview guide and data analysis (directed content analysis), supplemented by conventional content analysis (inductive content analysis) to identify emergent themes.</p><p><strong>Results: </strong>Nineteen HCPs (57.9% male, 42.1% female, 63.2% with more than 10 years of experience) were interviewed, including 14 rheumatologists, 3 pharmacists and 2 nurses. Findings related to domains \"environmental context and resources\", \"social influences\" and \"skills\" were frequently identified, whereas the domains \"intention\", \"reinforcement\" and \"emotion\" were least reported. The most prominent enablers related to HCPs' knowledge and skills. Necessary skills were grouped into communication, logistical planning, and patient selection. Other enablers included the accessibility of injection support services, availability of prefilled syringes and online resources for patients (\"environmental context and resources\") and social influences. The most common identified barriers related to the logistics of implementing parenteral methotrexate. Other barriers included issues with the Occupational Health and Safety guidelines, time constraints (\"environmental context and resources\"), concerns about patients withdrawing methotrexate from the vial (\"emotion\") and patients' low acceptability or affordability of the injectable medication (\"social influences\").</p><p><strong>Conclusion: </strong>Our findings suggest that training and guidance on selecting appropriate patients, utilization of systems to support education of patients and to minimize occupational exposure, and availability of patient-friendly devices would support greater implementation of parenteral methotrexate in practice.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"2026-2037"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consumers' experiences and perspectives on reporting adverse drug reactions using digital tools: a qualitative study.","authors":"Mohammed Gebre Dedefo, Gizat M Kassie, Eyob Alemayehu Gebreyohannes, Renly Lim, Elizabeth Roughead, Lisa Kalisch Ellett","doi":"10.1007/s11096-026-02193-1","DOIUrl":"10.1007/s11096-026-02193-1","url":null,"abstract":"<p><strong>Introduction: </strong>Spontaneous adverse drug reactions (ADRs) are underreported. Digital reporting systems are increasingly used to address this issue; however, limited knowledge exists about the barriers and facilitators influencing their use by consumers.</p><p><strong>Aim: </strong>To explore facilitators and barriers influencing consumers' use of digital tools for ADR reporting, and to identify the factors, expectations and preferences that affect their engagement with these tools.</p><p><strong>Method: </strong>An exploratory qualitative descriptive study using semi-structured in-depth interviews was conducted among Australian adults who self-reported having experienced an ADR. Interviews were conducted face-to-face or via Zoom, audio-recorded, transcribed verbatim, and analysed inductively using reflexive thematic analysis. Themes were mapped onto domains of the Combined Technology Acceptance Model and Theory of Planned Behaviour (C-TAM-TPB) framework.</p><p><strong>Results: </strong>Fourteen participants were interviewed. Consumers expressed positive intentions to use online ADR reporting tools. Identified facilitators included user-friendly and accessible tools that are simple to complete, the use of images to aid comprehension, integration with existing patient health records, the ability to submit reports to both healthcare professionals and regulators, and a tool designed specifically for consumers using layperson language. Identified barriers included lack of awareness that consumers could report ADRs using online tools, the need for registration, complex medical terminology, compulsory fields, and the absence of feedback after submission.</p><p><strong>Conclusion: </strong>Consumers were willing to use online ADR reporting tools but were largely unaware of their existence. Enhancing usability through user-friendly design, and reporting forms specifically designed for consumers may increase engagement. Addressing barriers such as lack of awareness, registration requirements, medical jargon, and lack of feedback may improve usability and contribute to strengthening pharmacovigilance systems.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"2094-2104"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring hospital pharmacist perspectives on ethical considerations from automated patient prioritisation: a qualitative study.","authors":"D Clifford, A Wall, A Kurdi, M Bennie","doi":"10.1007/s11096-026-02180-6","DOIUrl":"10.1007/s11096-026-02180-6","url":null,"abstract":"<p><strong>Introduction: </strong>The use of Hospital Electronic Prescribing and Medicines Administration (HEPMA) data in automated patient prioritisation (APP) tools is an emerging area of interest within pharmacy practice and research. As the Scottish Government continues to invest in digital transformation across health and social care, pharmacy professionals are increasingly required to adapt to new technologies whilst maintaining high standards of patient care. APP tools offer the potential to enhance operational efficiency and support clinical decision making. However, despite growing implementation internationally, there is a scarcity of published research exploring the ethical considerations associated with use.</p><p><strong>Aim: </strong>To explore hospital pharmacists' perspectives of ethical considerations from APP tool use prior to adoption in the hospital pharmacy setting.</p><p><strong>Method: </strong>Two focus groups were conducted with a total of 12 hospital pharmacists (Pharmacist Team Manager n = 2, Advanced Pharmacist n = 5, Specialist Pharmacist n = 3, Pharmacist n = 2) from a Scottish Health Board prior to the implementation of APP using the 'CoRE-Values' ethical decision-making framework, with the aid of a clinical vignette for context. Focus group transcripts were analysed thematically with the four domains of the framework as mapped themes.</p><p><strong>Results: </strong>Participants considered the use of APP to be a fair and pragmatic approach to managing daily workload, enabling pharmacy teams to focus on patients most at risk of medication related harm. However, professional judgement remains essential when interpreting APP outputs, and caution must be exercised to avoid an overreliance on automation. The clinical rules underpinning APP must be regularly reviewed to ensure alignment with current practice and emerging evidence. While complete visibility of high-risk patients offers significant clinical value, it may also expose limitations in workforce capacity. Participants noted that this visibility could be leveraged to support business case development to secure further staff resource and/or service transformation.</p><p><strong>Conclusion: </strong>APP use can support clinical decision making by directing pharmacy staff to patients at risk of medication related harm in hospitals, but ethical concerns can arise if organisations do not give due consideration to these issues prior to adoption.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"2005-2014"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148368268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing pharmacist practice through a pilot family practice preceptorship programme: a prospective quantitative pre-post evaluation.","authors":"Tamara M Cairney, Heather Harrison, Mairi-Anne McLean, Tania Ramos, David Kernaghan, Chris F Johnson","doi":"10.1007/s11096-026-02198-w","DOIUrl":"10.1007/s11096-026-02198-w","url":null,"abstract":"<p><strong>Introduction: </strong>Primary care health services face workforce pressures internationally. Greater multidisciplinary working is seen as a solution. In Scotland, pharmacists are embedded within primary care teams. General Practice Clinical Pharmacists (GPCPs) deliver medicines-related services, including independent prescribing, medicines optimisation and medication review. However, GPCPs' clinical experience and training vary considerably. A structured preceptorship programme was developed to support role development.</p><p><strong>Aim: </strong>To evaluate the impact of a preceptorship programme for GPCPs on self-assessed training needs, competence and confidence within routine primary care practice.</p><p><strong>Method: </strong>A prospective repeated-measures survey and medication review activity analysis were conducted with GPCPs in one health board between January 2024 and March 2025. Reported using the Checklist for Reporting of Survey Studies (CROSS). Preceptees, identified using eligibility criteria, completed a 32-item Hennessy-Hicks Training Needs Analysis questionnaire pre- and post a 12-week preceptorship programme, rating tasks for importance, self-perceived performance and confidence. Matched pre-post questionnaire responses were analysed using the Wilcoxon signed-rank test. Routinely recorded medication review activity was extracted from electronic clinical systems for six months pre- and post-programme and summarised descriptively.</p><p><strong>Results: </strong>Fifty-three GPCPs enrolled; 51 (96%) completed (median age 34 [range 24-57] years; 43 (84%) female. Median years qualified were 11 (range 1-33) and 3 years (0-10) primary care experience. Pre- to post-response rate was 76% (39/51). At baseline, the top five scoring self-reported priority training needs items (task importance minus perceived performance score) of the 32 items were: mental health and chronic pain reviews, conflict management, biopsychosocial assessment, and assessing patient decision-making capacity. At 12 weeks all scores had reduced, with larger reductions observed in the top five items (p < 0.001 for each item). Self-reported competence and confidence across all superordinate categories appeared to increase. Recorded medication review activity was summarised descriptively. Median monthly reviews increased from 2 (IQR 0-4) before preceptorship to 4 (IQR 1-10) during preceptorship, before returning to 2 (IQR 0-7) after programme completion.</p><p><strong>Conclusion: </strong>Structured preceptorship was associated with improved self-reported competence and confidence and a short-term increase in recorded medication review activity. Further evaluation is required to determine whether these changes translate into sustained clinical activity for improved patient outcomes.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"2128-2138"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}